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The emergence of genomics in the field of clinical 
genetics
Clinical genetics
§ Focus on monogenetic diseases
§ national networks of scientists, 
clinicians, funding bodies based 
around hospitals
§ clinical genetics centres linking 
laboratory research and 
diagnosis with clinical patient 
care and counselling
§ strong orientation of research to 
clinically relevant genetic 
diseases
§ important role for patient groups 
as intermediaries
Genomics 
§ Focus on multifactorial diseases
§ large-scale consortia with 
international, multi-disciplinary 
collaboration 
§ strategic public investments and 
public-private relationships
§ use of high throughput 
technologies
§ genetic databases as platforms 
linking academic and commercial 
interests
Genomics as a new innovation regime
§ Emergence of genomics involves an epistemological and institutional
transformation of knowledge production in human genetics
§ This transformation also has implications for the ways in which science 
and society are related in genomics
§ ‘Valorisation’ as a new challenge in genomics
§ “to ensure that society and economy benefit from the 
breakthrough enabled by genomics in important fields like health, 
sustainability, enabling technologies and society” (NGI homepage)
§ Measured in quantities of dissertations, patents, start-up 
companies, industrial matching  
§ Narrow economic definition leads to discrimination of particular research 
fields (eg. does not appreciate contribution to new diagnostic criteria)






§ Innovation regime refers to rules, procedures, and heuristics that guide
activities and interactions in networks of research and development
§ Resource driven regimes characterized by the exploration of multiple possible
paths
§ Technological regimes characterized by actor’s beliefs about ‘not yet
exploited opportunities’ along a specific path
§ Socio-technical paths refers to the (emerging) alignment between
activities of actors at different poles (science, industry, clinic)
à Valorization as knowledge production and uptake along paths towards 
clinical applications





Identity and roles of actors? 
Path dynamics?
Regime characteristics?
Implications for valorization? 
Two case studies
§ Duchenne Muscular Dystrophy
§ Major object of research in the clinical genetics regime (Nelis, 1998): 
monogenetic disease, strong patient involvement
§ Illustrates evolution of clinical genetics regime (e.g. current focus on
therapeutic interventions w/ commercial actors) 
§ Alzheimer’s disease
§ Typical genomics regime: multifactorial disease, use of large biobanks, 
association studies as emerging paradigm
§ Emerging regime: merging of different activities (epidemiological and 
genetic research) and new institutional forms (genetic epidemiology
departments)
Co-author map of Duchenne Muscular Dystrophy 
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Preliminary characterization of DMD regime
§ Actors: Center for Human and Clinical Genetics (LUMC), Prosensa, 
GlaxoSmithKline, DMD patients/parents/organisations
§ Path dynamics: alignment of scientific and industrial actors via patent, spin-
off Prosensa, exon skipping technology
§ Innovation regime driven by the prospect of a new therapy
§ Implications for valorization: 
§ Science-industry relations: scientists’ commercial ties, intellectual
property, societal benefits of public funding, distribution of risks?
§ (Clinical implications: exon skipping implies patient stratificationà
solidarity in patient organisation, orphanisation vs. clinical trials?)
Preliminary characterization of Alzheimer regime
§ Actors: epidemiologists, geneticists
§ Path dynamics
§ Explorative, multiple possible paths
§ Resource driven regime: availability of abundant data and genotyping
technology, complex agenda, hypothesis generation and testing
§ Implications for valorization: 
§ If one would equally appreciate the work done in fields like Alzheimer’s
genomics, then another notion of valorization is required: one based on
the possibility of ‘path creation’ instead of ‘path dependency’
§ Management of expectations, co-creation of scenarios, interactions
between different paths (diagnosis, detection, prevention, therapy), 
knowledge uptake, long-term resource availability
To wrap up
§ Emergence of medical genomics in the field of clinical genetics
§ Clinical genetics and medical genomics are governed by different types of 
regimes, with implications for valorisation policy
§ Economic valorisation feasible in case of established technological regime 
(clinical genetics regime of Duchenne research)
§ Beyond narrow definition: Valorisation as mid- and long-term accountability
of path creation
§ Legitimacy of possible scenarios of future developments
